CFO4Life Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | – | Sell |
-4,672
| Closed | -$285K | – | 232 |
|
2025
Q1 | $285K | Buy |
4,672
+322
| +7% | +$19.6K | 0.05% | 164 |
|
2024
Q4 | $246K | Sell |
4,350
-38
| -0.9% | -$2.15K | 0.04% | 179 |
|
2024
Q3 | $227K | Buy |
+4,388
| New | +$227K | 0.04% | 184 |
|
2024
Q2 | – | Sell |
-4,300
| Closed | -$233K | – | 208 |
|
2024
Q1 | $233K | Buy |
+4,300
| New | +$233K | 0.04% | 169 |
|
2023
Q4 | – | Sell |
-3,891
| Closed | -$226K | – | 188 |
|
2023
Q3 | $226K | Buy |
3,891
+123
| +3% | +$7.14K | 0.05% | 138 |
|
2023
Q2 | $241K | Buy |
3,768
+332
| +10% | +$21.2K | 0.05% | 143 |
|
2023
Q1 | $238K | Sell |
3,436
-401
| -10% | -$27.8K | 0.05% | 141 |
|
2022
Q4 | $276K | Buy |
3,837
+306
| +9% | +$22K | 0.06% | 140 |
|
2022
Q3 | $251K | Sell |
3,531
-181
| -5% | -$12.9K | 0.07% | 115 |
|
2022
Q2 | $274K | Sell |
3,712
-22
| -0.6% | -$1.62K | 0.07% | 118 |
|
2022
Q1 | $273K | Buy |
3,734
+25
| +0.7% | +$1.83K | 0.06% | 125 |
|
2021
Q4 | $231K | Sell |
3,709
-768
| -17% | -$47.8K | 0.05% | 136 |
|
2021
Q3 | $265K | Buy |
4,477
+270
| +6% | +$16K | 0.06% | 121 |
|
2021
Q2 | $281K | Sell |
4,207
-11
| -0.3% | -$735 | 0.06% | 114 |
|
2021
Q1 | $266K | Sell |
4,218
-6,938
| -62% | -$438K | 0.07% | 123 |
|
2020
Q4 | $692K | Buy |
11,156
+10
| +0.1% | +$620 | 0.2% | 57 |
|
2020
Q3 | $672K | Buy |
11,146
+1,895
| +20% | +$114K | 0.23% | 51 |
|
2020
Q2 | $544K | Buy |
9,251
+1,475
| +19% | +$86.7K | 0.21% | 51 |
|
2020
Q1 | $433K | Buy |
+7,776
| New | +$433K | 0.23% | 59 |
|
2018
Q1 | – | Sell |
-3,931
| Closed | -$241K | – | 96 |
|
2017
Q4 | $241K | Hold |
3,931
| – | – | 0.19% | 85 |
|
2017
Q3 | $251K | Buy |
+3,931
| New | +$251K | 0.2% | 85 |
|